Article
However, IOP remains most important risk factor for blindness
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Cosmetic procedures associated with serious ophthalmologic complications
3 Things You Should Know About Interventional Glaucoma Comanagement
Q&A: Michael Lai, MD, PhD, on the impact of underfunding the Good Days program
Patient-Centered Treatment Strategies in the Management of nAMD and DME
Clearside Biomedical's Xipere (triamcinolone acetonide injectable suspension) approved by Health Canada
Q&A: PER-001 showed improved structure and visual function in patients with diabetic retinopathy